Scrip ID
PHARMAID
Pharmaids Pharmaceuticals Limited has filed a regulatory disclosure with BSE Limited regarding an upcoming board meeting.
A meeting of the Board of Directors is scheduled to be held on Wednesday, November 11, 2026. The primary agenda includes consideration and approval of the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026.
Regarding insider trading compliance, the company confirms that the Trading Window for dealing in the company's securities remains closed from October 1, 2026. This closure is in continuation of the earlier intimation dated September 25, 2026, and is pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Company's Code of Conduct and Policies for Prevention of Insider Trading. The Trading Window will re-open after 48 hours from the declaration of the financial results.
This information is also available on the Company's website at www.pharmaids.com.
The disclosure is signed by Prasanna Subramanya Bhat, Company Secretary & Compliance Officer, on November 5, 2026 at 17:38:36 IST.